title: Is there a role for 'modified VAD' in the treatment of multiple myeloma?
abstract: VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, VAD can no longer be proposed in preparation to autologous transplantation, although there are still indications that VAD remains useful and clinically relevant in the initial treatment of symptomatic multiple myeloma.
authors.affiliation: Haematoncology Division, European Institute of Oncology, Via Ripamonti 435, Milan, 20141, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Agazzi
authors.forename: S
authors.initials: S
authors.lastname: Sammassimo
authors.forename: D
authors.initials: D
authors.lastname: Laszlo
authors.forename: Sj
authors.initials: S
authors.lastname: Liptrott
authors.forename: R
authors.initials: R
authors.lastname: Cascio
authors.forename: A
authors.initials: A
authors.lastname: Alietti
authors.forename: C
authors.initials: C
authors.lastname: Rabascio
authors.forename: P
authors.initials: P
authors.lastname: Mancuso
authors.forename: G
authors.initials: G
authors.lastname: Pruneri
authors.forename: G
authors.initials: G
authors.lastname: Martinelli